Alzheimer’s disease, Parkinson’s disease, ALS, and other proteopathies are not uniform diseases. Each comprises multiple molecular subtypes, driven by combinations of proteins that misfold and clump together – a process known as pathological protein aggregation.

seragy decodes these diseases and makes protein aggregates measurable. Its proprietary SeRAS® platform aims to amplify tiny traces of misfolded protein, so-called seeds, from patient samples and turn them into molecular fingerprints. These fingerprints reveal disease subtypes and provide quantitative translational biomarkers for targeted drug development.